Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA1 | P00915 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA4 | P22748 | 1/20 | 0.70 |
| ▸ | CA6 | P23280 | 1/20 | 0.70 |
| ▸ | CA7 | P43166 | 1/20 | 0.70 |
| ▸ | TPMT | P51580 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11801641 | 0.85 | TSHR (0.76) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL1493250 | 0.84 | CYP1A2 (1.00) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL29618985 | 0.84 | TSHR (0.76) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL3758910 | 0.84 | TSHR (0.76) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL409710 | 0.83 | MEN1 (0.75) | CYP1A2ALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL335681 | 0.83 | MAPK1 (0.77) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL76834 | 0.83 | TSHR (0.73) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| Veratric Acid SCHEMBL976032 | 0.83 | CA12 (1.00) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL9364577 | 0.83 | CYP1A2 (0.96) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL29415167 | 0.83 | MAPK1 (0.77) | TSHRCYP2C9CYP2C19CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365196-B2 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK SHARP & DOHME LTD. (GB) | 2008-04-29 | — | — | US | disclosed |
| EP-1268412-B8 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2007-02-21 | — | — | EP | disclosed |
| EP-1268412-B1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME (GB) | 2006-11-22 | — | — | EP | disclosed |
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | MERCK CANADA INC. (CA) | 2004-02-12 | — | — | US | disclosed |
| EP-1268412-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070677-A1 | SULPHONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 2001-09-27 | — | — | WO | disclosed |
| EP-0194161-B1 | Cyclopenta[d]pyrimidine derivatives, their preparation and use | SANKYO CO (JP) | 1994-05-25 | — | — | EP | disclosed |
| US-4749704-A | Cyclopenta[d]pyrimidine derivatives and use as antidepressants | SANKYO COMPANY LIMITED (JP) | 1988-06-07 | — | — | US | disclosed |
| EP-0194161-A2 | Cyclopenta[d]pyrimidine derivatives, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1986-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029862-A1 | Sulphonamido-substituted bridged bicycloalkyl derivatives | BACE1, BACE2, PSEN2 | TSHR 4669/4885CYP2C9 2521/4885CYP2C19 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.